IGF1R Gene Editing


Our promise to you:
Guaranteed product quality, expert customer support.


IGF1R Gene Editing    

The Insulin-like Growth Factor Receptor (IGF1R), also known as CD221/JTK13, is a transmembrane receptor found on the surface of human cells and belongs to the large class of tyrosine kinase receptors, mediates the effects of IGF-1. IGF1R is activated by hormone called insulin-like growth factor 1 (IGF-1), a polypeptide protein hormone similar to insulin in molecular structure, and by the related growth factor IGF-2. IGF1R is a hetero-tetrameric protein with two identical extracellular α-subunits and two transmembrane β-subunits. The extracellular domain contains a cysteine-rich IGF-binding site. The transmembrane domain contains tyrosine kinase activity which depends on an ATP-binding site (lys1003) and a cluster of three tyrosine residues at positions 1131, 1135, and 1136. Activation of IGF1R initiates a cascade of downstream signaling pathways (Figure 1).

 Schematic representation of the IGF-1R signaling network and nodes of therapeutic blockadeFigure1. Schematic representation of the IGF-1R signaling network and nodes of therapeutic blockade (Wade T. et al. 2015)

The IGF1R signaling pathway, while cell type-specific, is critical for cell proliferation, growth, and survival. Lots of studies have showed that the IGF1R is implicated in a number of cancers including breast, prostate, and lung cancers. As a result, IGF1R appears to be a key factor in numerous cancer therapies and a potential therapeutic target for many different malignancies. IGF1R signaling is a complex and tightly regulated network, interacting with and influencing various cellular components including ER, EGFR, HER-2, and the DNA damage response pathway. It is through these interactions that IGFIR appears allow cancer cells to resist cytotoxicity and targeted therapies. Although many of these therapeutic agents are now undergoing clinical trials, how most effectively inhibit IGF1R action and enhance the response of tumor cells to treatment still requires further research. There is still a long way to go in terms of drug development for this pathway.

IGF1R Gene Editing Service

With our experienced Crispr-Cas9 gene-editing scientist team, CRISPR/Cas9 PlatformCB provides you with the most professional and comprehensive IGF1R gene-editing services in a shorter time. CRISPR/Cas9 PlatformCB at Creative Biogene can provide you custom IGF1R knock-out or knock-in cell and animal model services to meet your specific project needs and provide experienced scientific support at every step.

  • IGF1R Gene Editing Cell Line Generation

Using CRISPR technology, CRISPR/Cas9 PlatformCB has successfully implemented gene editing of IGFR in a variety of cell lines, including easy-to-transfect cell lines and hard-to-transfect cells. Our full cell line generation service cover from sgRNA design/construction to final cell line generation/verification. As each project is different, we also provide you with one-stop services for custom IGF1R gene editing cell line you desire generation service, including point mutation and gene insertion, conditional knock-out/knock-in.

Our IGF1R gene editing cell line generation services include:

✧ SgRNA design and synthesis
✧ Transfect the cell line you interest
✧ Select the high expression cell and sort monoclonal cell
✧ Validate the knockout/knockin/point mutation of IGF1R by PCR and sequencing
✧ Produce cryogenic preserved vials of stable cells and a final report

Alternative host cell line: Ba/F3, CHO, HEK293, HEK239T, Hela, MDA-MB-453, MDA-MB-231NIH3T3, T47D, Neuro2a, HepG2, MCF7, RKO, K562, RAW264.7, et al.

  • IGF1R Gene Editing Animal Model Generation

As CRISPR enabled targeted genome editing in a simple, efficient, and economical manner, the process of creating transgenic animals became simpler. CRISPR/Cas9 PlatformCB has extensive experience in manipulating animal embryos and been very successful in incorporating CRISPR-Cas9 technology into our program, which have been well recognized by our customers. Based on our research platform and team of scientists, we can produce IGF1R transgenic and gene-targeted animals at a reasonable cost in a shorter time. Our IGF1R gene editing animal model generation services include:

➢ IGF1R gene conventional knockout animals
➢ IGF1R gene conditional knockout animals
➢ IGF1R point mutation animals
➢ IGF1R knockin animals

Alternative species: mouse, rat, rabbit, zebrafish, C. elegans, etc.

CRISPR/Cas9 PlatformCB is professional in providing custom genome engineering projects. Based on national advanced laboratory platforms, professional team and efficient operation, we guarantee our clients the most reliable and efficient research services to best match your research goals. If you don't see the gene editing service related to IGFR1 you need above, don't hesitate to contact us.

Related Products at CRISPR/Cas9 PlatformCB


  1. Luigi Laviola etc. The IGF-I Signaling Pathway. Current Pharmaceutical Design. 2007, 13, 663-669.
  2. Jones JI, Clemmons DR. "Insulin-like growth factors and their binding proteins: biological actions". Endocrine Reviews. 1995. 16 (1): 3–34.
  3. LeRoith D. etc. Molecular and cellular aspects of the insulin-like growth factor I receptor". Endocrine Reviews. 1995. 16 (2): 143–63.
  4. Wade T. Iams and Christine M. Lovly. Molecular Pathways: Clinical Applications and Future Direction of Insulin-Like Growth Factor-1 Receptor Pathway Blockade. Clin Cancer Res. 2015 Oct 1; 21(19): 4270–4277.
  5. Angelo J. etc. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Frontiers in Bioscience. 2008. 13, 3273-3287.
For research use only. Not intended for any clinical use.


Please input "biogene" as verification code.